AIM: To investigate the role of enhancer of zeste homologue 2 (EZH2) and STAT6 immunohistochemistry in the evaluation of clinical stages and prognosis of colorectal cancer (CRC). METHODS: The expression patterns were examined by immunohistochemistry in both tumor and adjacent non-neoplastic tissues of 119 CRC patients who underwent operation during the time period from 2002 to 2004. RESULTS: The positive rates of EZH2 and STAT6 in CRC cases were 69.7% (83 of 119) and 60.5% (72 of 119), respectively, and there was significant difference when compared with tumor adjacent non-neoplastic tissues (P < 0.05). In all CRC cases, patients with EZH2-positive, or STAT6-positive expression had lower survival rates than those with EZH2-negative or STAT6-negative expression (P = 0.002 and P = 0.005, respectively). Co-expression of EZH2 and STAT6 showed significantly higher levels in CRC cases of high clinical TNM stages (P = 0.001), and the expression of STAT6 was also correlated with lymph node metastasis and distant metastasis (P = 0.001 and P = 0.016, respectively). Multivariate analysis revealed that EZH2 expression was an independent prognostic indicator of CRC (P = 0.039). CONCLUSION: EZH2 and STAT6 expressions have significant values in distinguishing clinical stages of CRC and predicting the prognosis of the patients.
AIM: To investigate the role of enhancer of zeste homologue 2 (EZH2) and STAT6 immunohistochemistry in the evaluation of clinical stages and prognosis of colorectal cancer (CRC). METHODS: The expression patterns were examined by immunohistochemistry in both tumor and adjacent non-neoplastic tissues of 119 CRC patients who underwent operation during the time period from 2002 to 2004. RESULTS: The positive rates of EZH2 and STAT6 in CRC cases were 69.7% (83 of 119) and 60.5% (72 of 119), respectively, and there was significant difference when compared with tumor adjacent non-neoplastic tissues (P < 0.05). In all CRC cases, patients with EZH2-positive, or STAT6-positive expression had lower survival rates than those with EZH2-negative or STAT6-negative expression (P = 0.002 and P = 0.005, respectively). Co-expression of EZH2 and STAT6 showed significantly higher levels in CRC cases of high clinical TNM stages (P = 0.001), and the expression of STAT6 was also correlated with lymph node metastasis and distant metastasis (P = 0.001 and P = 0.016, respectively). Multivariate analysis revealed that EZH2 expression was an independent prognostic indicator of CRC (P = 0.039). CONCLUSION:EZH2 and STAT6 expressions have significant values in distinguishing clinical stages of CRC and predicting the prognosis of the patients.
Authors: Zuyao Ni; Wei Lou; Soo Ok Lee; Rajiv Dhir; Fernando DeMiguel; Jennifer Rubin Grandis; Allen C Gao Journal: J Urol Date: 2002-04 Impact factor: 7.450
Authors: G Laible; A Wolf; R Dorn; G Reuter; C Nislow; A Lebersorger; D Popkin; L Pillus; T Jenuwein Journal: EMBO J Date: 1997-06-02 Impact factor: 11.598
Authors: F M Raaphorst; F J van Kemenade; T Blokzijl; E Fieret; K M Hamer; D P Satijn; A P Otte; C J Meijer Journal: Am J Pathol Date: 2000-09 Impact factor: 4.307
Authors: Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan Journal: Nature Date: 2002-10-10 Impact factor: 49.962
Authors: Suzanne Ostrand-Rosenberg; Pratima Sinha; Virginia Clements; Samudra I Dissanayake; Seth Miller; Cordula Davis; Erika Danna Journal: Cancer Immunol Immunother Date: 2003-10-30 Impact factor: 6.968
Authors: Celina G Kleer; Qi Cao; Sooryanarayana Varambally; Ronglai Shen; Ichiro Ota; Scott A Tomlins; Debashis Ghosh; Richard G A B Sewalt; Arie P Otte; Daniel F Hayes; Michael S Sabel; Donna Livant; Stephen J Weiss; Mark A Rubin; Arul M Chinnaiyan Journal: Proc Natl Acad Sci U S A Date: 2003-09-19 Impact factor: 11.205
Authors: Elizabeth G Demicco; Paul W Harms; Rajiv M Patel; Steven C Smith; Davis Ingram; Keila Torres; Shannon L Carskadon; Sandra Camelo-Piragua; Jonathan B McHugh; Javed Siddiqui; Nallasivam Palanisamy; David R Lucas; Alexander J Lazar; Wei-Lien Wang Journal: Am J Clin Pathol Date: 2015-05 Impact factor: 2.493
Authors: Lauren Krill; Wei Deng; Ramez Eskander; David Mutch; Susan Zweizig; Bang Hoang; Olga Ioffe; Leslie Randall; Heather Lankes; David S Miller; Michael Birrer Journal: Gynecol Oncol Date: 2019-12-13 Impact factor: 5.482
Authors: Carmen Behrens; Luisa M Solis; Heather Lin; Ping Yuan; Ximing Tang; Humam Kadara; Erick Riquelme; Hector Galindo; Cesar A Moran; Neda Kalhor; Stephen G Swisher; George R Simon; David J Stewart; J Jack Lee; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531